43,531 Shares in Organon & Co. (NYSE:OGN) Bought by Dark Forest Capital Management LP

Dark Forest Capital Management LP acquired a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 43,531 shares of the company's stock, valued at approximately $649,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Pacer Advisors Inc. raised its position in Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after purchasing an additional 11,140,388 shares during the period. Norges Bank bought a new position in shares of Organon & Co. during the fourth quarter valued at approximately $25,258,000. Magnetar Financial LLC raised its holdings in shares of Organon & Co. by 560.2% in the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company's stock worth $25,878,000 after buying an additional 1,471,731 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Organon & Co. by 23.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company's stock valued at $48,999,000 after acquiring an additional 629,191 shares during the period. Finally, Invesco Ltd. boosted its holdings in Organon & Co. by 44.6% during the 4th quarter. Invesco Ltd. now owns 2,034,780 shares of the company's stock valued at $30,359,000 after acquiring an additional 627,944 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Trading Up 0.7 %

NYSE OGN opened at $12.21 on Friday. Organon & Co. has a one year low of $10.45 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a market capitalization of $3.15 billion, a price-to-earnings ratio of 3.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The company's 50-day simple moving average is $13.86 and its two-hundred day simple moving average is $15.18.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Equities analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 9.17%. Organon & Co.'s dividend payout ratio is presently 33.63%.

Analyst Upgrades and Downgrades

OGN has been the subject of several research analyst reports. TD Cowen upgraded Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Morgan Stanley reduced their target price on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Finally, Barclays lowered their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Organon & Co. has a consensus rating of "Hold" and an average target price of $20.60.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.